AstraZeneca and Merck receive US FDA extension for Lynparza review

(Alliance News) - AstraZeneca PLC on Thursday alongside US peer Merck & Co, announced that the US ...

Alliance News 15 December, 2022 | 8:37AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - AstraZeneca PLC on Thursday alongside US peer Merck & Co, announced that the US Food & Drug Administration will extend the Prescription Drug User Fee Act date by three months to allow further time for a full review of the supplementary new drug application of Lynparza in combination with abiraterone and prednisone or prednisolone.

The review is for Lynparza in combination for the treatment of metastatic castration-resistant prostate cancer.

Last month, EU's Medicines Agency Committee for Medicinal Products for Human Use recommended to approve Lynparza in combination with abiraterone and prednisone or prednisolone in the EU for the treatment of the aforementioned cancer, for people who are not clinically indicate to undergo chemotherapy.

AstraZeneca shares were 0.6% lower at 11,328.00 pence each on Thursday morning in London.

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 12,556.00 GBX -0.27
Merck & Co Inc 130.67 USD 0.11

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures